Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Entera Bio

  • Phillip Schwartz, Entera Bio

Company Profile

Entera Bio is a product-focused biotechnology company specializing in the oral delivery of large molecules and biologics.

Entera Bio is currently conducting clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the GI tract.

Entera Bio's technology addresses the two major problems of oral drug delivery of large molecule APIs (active pharmaceutical ingredients). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract.

Entera’s Proprietary Technologies Act Synergistically to Transport and Protect Large Molecules.

  • Date:Tuesday, February 12
  • Time:9:15 AM - 9:30 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23602
  • Goal for Presentation:Business Development
  • Company Website:Entera Bio
  • Company HQ City:Jerusalem
  • Company HQ Country:Israel
  • Ticker:ENTX
  • Exchange:NASDAQ
  • CEO/Top Company Official:Phillip Schwartz
  • Year Founded:2010
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development:Hypoparathyroidism
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):2
Speakers
Phillip Schwartz
Entera Bio
Back